MetabolismNews.net

Metabolism Xagena

Data, published in The Lancet, from two phase 3 studies, RUTHERFORD-2 and TESLA with Evolocumab, a novel investigational low-density lipoprotein cholesterol ( LDL-C )-lowering medication, resulted in ...


Results from four Phase 3 ODYSSEY trials of Alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin / k ...


By inhibiting apolipoprotein B ( ApoB ) synthesis, Mipomersen ( Kynamro ) can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients. The purpose of a study was to ascer ...


Homozygous familial hypercholesterolaemia ( HoFH ) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol ( LDL-C ) and accel ...


A meta-analysis of individual participant data of eight prospective cohort studies from Europe and the US has investigated the association between serum 25-hydroxyvitamin D concentrations [ 25(OH)D ] ...


Thirty-six percent of adults in the United States are obese, and many cannot lose sufficient weight to improve health with lifestyle interventions alone. Researches have conducted a systematic revi ...


National and international guidelines recommend fasting lipid panel measurement for risk stratification of patients for prevention of cardiovascular events. Yet, the prognostic value of fasting versus ...


Vitamin-D insufficiency is associated with many disorders, leading to calls for widespread supplementation. Some investigators suggest that more clinical trials to test the effect of Vitamin-D on diso ...


In short-term randomized trials ( duration, 1 to 2 years ), bariatric surgery has been associated with improvement in type 2 diabetes mellitus. Researchers have assessed outcomes 3 years after the ...


Efficacy and safety of Alirocumab were compared with Ezetimibe ( Ezetrol, Zetia ) in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy ...


Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced pla ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of Calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


Amgen has announced that the Phase 3 RUTHERFORD-2 ( RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2 ) trial evaluating Evolocumab in combination ...


Current osteoporosis medications increase bone mineral density ( BMD ) modestly and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering anabolic agents and bisph ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


The results from a phase 2 trial evaluating Romosozumab in postmenopausal women with low bone mineral density ( BMD ) were published in the New England Journal of Medicine ( NEJM ).The trial demonstra ...


Rhizomelic chondrodysplasia punctata ( RCDP ) is a rare disorder of peroxisomal metabolism, with an estimated incidence of 1:100.000. There are 3 genetic subtypes. RCDP type 1, caused by mutations in ...


Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. A study has assessed the efficacy and safety of the microsomal triglyceride transfer protein ( MTP ) inh ...


Enteral nutrition is recommended for patients in the intensive-care unit ( ICU ), but it does not consistently achieve nutritional goals.Researchers have assessed whether delivery of 100% of the energ ...


Statins are commonly prescribed for management of dyslipidaemia and cardiovascular disease. Increased fitness is also associated with low mortality and is recommended as an essential part of promoting ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati